UniQure’s gene therapy AMT-061 looking promising mid trial
UniQure’s experimental gene therapy has shown sustained Factor IX activity in a Phase II study assessing its potential to treat haemophilia B.
Read More
Tag: AMT-061
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
